rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
 just released nejm: ph 3 trial rucaparib mcrpc patients w/brca1, brca2, atm after 2nd gen arpi. 62 mo rpfs 11.2 mo vs 6.4 mo(ruc vs control) hr 0.50; itt group(10.2 mo vs 6.4 mo, hr, 0.61) atm rpfs (8.1 mo vs 6.8 mo) #gu23 
🎗Oncologist|🧬Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter